Cargando…

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis

INTRODUCTION: The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing–remitting (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dupuy, Sheena L., Tauhid, Shahamat, Hurwitz, Shelley, Chu, Renxin, Yousuf, Fawad, Bakshi, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130921/ https://www.ncbi.nlm.nih.gov/pubmed/27744504 http://dx.doi.org/10.1007/s40120-016-0054-4

Ejemplares similares

Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability
por: Chu, Renxin, et al.
Publicado: (2017)

Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines
por: Chu, Renxin, et al.
Publicado: (2018)

The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis
por: Yousuf, Fawad, et al.
Publicado: (2016)

Whole‐brain atrophy assessed by proportional‐ versus registration‐based pipelines from 3T MRI in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2018)

An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis
por: Kim, Gloria, et al.
Publicado: (2016)

The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
por: Singhal, Tarun, et al.
Publicado: (2016)

Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study
por: Singhal, Tarun, et al.
Publicado: (2019)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors
por: Dell’Oglio, Elisa, et al.
Publicado: (2015)

Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis
por: Bakshi, Rohit, et al.
Publicado: (2016)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis
por: Kim, Gloria, et al.
Publicado: (2015)

Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis
por: Chu, Renxin, et al.
Publicado: (2016)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Regional microglial activation in the substantia nigra is linked with fatigue in MS
por: Singhal, Tarun, et al.
Publicado: (2020)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

A dual modeling approach to automatic segmentation of cerebral T2 hyperintensities and T1 black holes in multiple sclerosis
por: Valcarcel, Alessandra M., et al.
Publicado: (2018)

Gray Matter Atrophy to Explain Subclinical Oculomotor Deficit in Multiple Sclerosis
por: Kincses, Bálint, et al.
Publicado: (2019)

Correlation between white matter damage and gray matter lesions in multiple sclerosis patients
por: Han, Xue-mei, et al.
Publicado: (2017)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Dual‐Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI
por: Meier, Dominik S., et al.
Publicado: (2017)

Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis
por: Lin, Aiyu, et al.
Publicado: (2013)

Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases
por: Hemond, Christopher C., et al.
Publicado: (2021)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Identifying miRNAs in multiple sclerosis gray matter lesions that correlate with atrophy measures
por: Tripathi, Ajai, et al.
Publicado: (2021)

Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer’s disease
por: Dong, Haoyang, et al.
Publicado: (2023)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mamqto2o2hiht6s81ee0ae2cra